Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
Epilepsy, Drug Resistant
Interventions
DRUG

Sirolimus

Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 0.5 mg per dose for BSA \<1.2 m², 1 mg per dose for BSA 1.3-2.1 m², and 1.5 mg per dose for BSA \>2.2 m².

Trial Locations (1)

Unknown

RECRUITING

Xuanwu Hospital, Beijing

All Listed Sponsors
collaborator

Peking University

OTHER

lead

Xuanwu Hospital, Beijing

OTHER